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Context: The Dutch T4-TSH-TBG-based neonatal screening pro-
gram detects patients with congenital hypothyroidism (CH) of thy-
roidal (CH-T) as well as central (CH-C) origin. The numbers and
characteristics of true-positive and false-positive referrals will dif-
fer from other, predominantly TSH-based, screening methods.
Objective: The present study describes the characteristics of the
referred neonates, both CH patients and false positives, and of the
reported CH patients with a false-negative screening result born in
the study period.
Design, Setting, Patients, andMain OutcomeMeasure: For each
referred child born between April 1, 2002, and May 31, 2004, screening
results and first venous sample results were recorded and classified as
transient or permanent CH-T or CH-C or as no CH.
Results: In the study period, 430,764 children were screened. Of the
772 children with abnormal screening results, 224 (29%) had CH;
another 13 CH patients did not have abnormal screening results,
giving an overall CH incidence of 1:1800. Incidences of permanentCH,
permanent CH-T, permanent CH-C, and transient CH were 1:2200,
1:2500, 1:21,000, and 1:12,000, respectively. The most frequent ex-
planations for the 548 false-positive referrals (71% of the referred
cohort) were severe illness and TBG deficiency (occurring in 198 and
200 children, respectively).
Conclusions: The Dutch incidence figures for CH belong to the high-
est worldwide, suggesting that the T4-TSH-TBG screening program
is an efficient method to detect CH of variable etiology and severity.
Still, a small percentage of children with CH escaped detection via
this screening approach. Severe illness and TBG deficiency appear to
be responsible for the majority of false-positive referrals. (J Clin
Endocrinol Metab 91: 3370–3376, 2006)
THYROID HORMONE IS important for normal devel-opment of the central nervous system (1). The critical
period for the central nervous system to be dependent on
thyroid hormone is known to extend from fetal life until at
least the first 2 yr after birth (2, 3). Therefore, children with
congenital hypothyroidism (CH), if left untreated, are at risk
for impaired cognitive and motor development. In many
countries, neonatal screening programs have been instituted
aiming to prevent cerebral damage by early initiation of T4
supplementation.
Several countries, such as Japan, Australia, and most Eu-
ropean countries, have a TSH-based screening program,
whereas many states in North America have a T4-based
screening program with additional measurement of TSH in
the samples with the lowest T4 concentration. Both strategies
are capable of detecting CH of thyroidal origin (CH-T), but
will miss (the majority of) patients with CH of central origin
(CH-C) (4). Recently, the Dutch T4-TSH-TBG screening
method has proven its outstanding ability to detect patients
with CH-T as well as CH-C (5–7), and the extra costs com-
pared with other screening methods are acceptable (4).
In addition to the difference in the proportion of patients
with CH-T and CH-C detected by a T4-TSH-TBG screening
method (true positives) compared with other methods, such
an approach may also have consequences for the numbers
and characteristics of patients with an abnormal screening
result but without CH (false positives). In the present study,
thyroid hormone determinants and clinical characteristics
were analyzed for all children born in a 2-yr period with an
abnormal screening result (true and false positives) and of
the reported patients with CH not detected by the neonatal
screening (false negatives). This design allowed us: 1) to
investigate the capability of the T4-TSH-TBG method to de-
tect CH of various etiology and severity; and 2) to calculate
the incidence of various types of CH.
Patients and Methods
Screening method (Fig. 1)
The Dutch neonatal CH screening method is primarily based on T4
measurement in filter paper blood spots. Sampling is performed be-
tween 4 and 7 d after birth. The concentration of T4, expressed as sd
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score, is compared with the day mean. If T4 is 0.8 sd or less, TSH
concentration (expressed in microunits per milliliter) is additionally
measured. If T4 is 1.6 sd or less, TBG concentration (expressed in
nanomoles per liter) is also measured. A T4/TBG ratio is calculated as
follows: (T4 sd  5.1)  [TBG]
1  1000. If T4 is 3.0 sd or less or TSH
is 50U/ml ormore, children are immediately referred to a pediatrician.
In case of a dubious result (3.0  T4 0.8 sd in combination with a
T4/TBG ratio  8.5 and/or 20  TSH  50 U/ml), a second heel
puncture is performed and T4, TSH, and TBG are repeated. Children are
referred to a pediatrician after a second heel puncture if the result is
dubious again or abnormal (4). For children born with a gestational age
(GA) of 36.0wk or less in combinationwith a birthweight (BW) of 2500 g
or less, the referral criterion is based on TSH; if TSH is at least 50 U/ml,
the child is referred, if TSH is at least 20 U/ml but less than 50 U/ml,
the result is considered dubious and a second heel puncture is per-
formed, after which the child is referred if the result is dubious again or
abnormal (4).
In the following text, abnormal screening result refers to one heel
puncture sampling with an abnormal screening result or two with a
dubious result.
Patients
The study was coordinated and executed by the department of pe-
diatric endocrinology of the Emma Children’s Hospital Academic Med-
ical Center (AMC) in collaboration with the Dutch Health Administra-
tions (DHA) and The Netherlands Organization of Applied Scientific
Research (TNO). The study protocol was approved by the Institutional
Review Board (which judges medical ethical aspects of research pro-
posals) of the AMC and the Privacy Committee of the Dutch CH Screen-
ing Board (which judges logistic, scientific, and ethical aspects of re-
search proposals concerning neonatal screening). The studied patients,
living all over the country, were not actually referred to the Emma
Children’s Hospital AMC; only their medical data were recorded.
When a child is born in The Netherlands, parents get a heel puncture
package with written information upon registering the birth of their
child. When the health worker visits the parents’ home, the heel punc-
ture is performed only after parents give their implicit consent.
The regional CH screening laboratory notifies the DHA on abnormal
and dubious CH screening results. Whenever referral to a pediatrician
is indicated, the DHA immediately contacts the general practitioner. For
those children born from April 1, 2002, until May 31, 2004 (referred to
as the study period), with an indication for referral, the DHA has sent
faxes with data containing heel puncture results, GA, BW, and the name
of the general practitioner to the AMC. This enabled the researchers of
the AMC to contact the pediatrician and ask for the laboratory and
clinical data of the referred child.
TNO documents the screening results and diagnostic findings of
Dutch children with abnormal screening results and data of CH patients
missed by neonatal screening, when reported by pediatricians. All local
hospitals can determine free T4 (FT4) and TSH, but for less common
thyroid function tests (such as TBG, thyroglobulin, or T3), material has
to be sent to a few specialized laboratories (e.g. the AMC). Tests for
urinary iodine and low-molecular-weight iodinated material are exclu-
sively performed in theAMC. TheAMCkeeps records of patientswhose
blood or urine samples were sent to confirm or specify the diagnosis of
CH or whose pediatrician consulted the Department of Pediatric En-
docrinology for advice. Usually this concerns referred patients with
abnormal CH screening results, but occasionally the records belong to
CH patients with normal screening results (false negatives). To get the
most complete cohort of CH patients born in the study period, datasets
of TNO and AMC were combined.
Classification based on screening results and
diagnostic work-up
For all subjects born during the study period, CH screening results,
first venous plasmaFT4 andTSH (andoptionally TBG),GA, BW, and any
remarkable clinical characteristics (e.g. family history and maternal thy-
roid function) were recorded. Based on the provided information, di-
agnosis was classified as no CH, transient CH, or permanent CH. The
category of no CHwas subdivided according to the alleged reason of the
abnormal screening result: severe illness, TBG deficiency (total when
heel puncture TBG was 0.3 mg/dl, i.e. 50 nmol/liter; partial when
0.3 mg/dl  heel puncture TBG  1.8 mg/dl, i.e. 50  TBG  300
nmol/liter), errors in the screening procedure, exchange blood trans-
fusion, delayed blood sampling, pre-/dysmaturity, and no obvious ex-
planation. The diagnosis of transient CH was further classified into
transient CH-T or transient CH-C. When known, the cause of transient
CH was documented. The diagnosis of permanent CH was further
classified into CH-T, CH-T21 (i.e. CH-T related to trisomy 21) (8), CH-C,
or CH not yet specified.
FIG. 1. Schematic presentation of the Dutch
screening procedure: laboratory tests, interpre-
tation, and decision. *, From January 1, 2005,
the cutoff for TSH is lowered from 20 to 18 mU/
liter.
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Reference ranges for children born at term at the age of 2–6 wk for
T4, FT4, TSH, and TBG are 6.5–16.3 g/dl (84–210 nmol/liter), 0.9–2.2
ng/dl (12–28 pmol/liter), 1.7–9.1 U/ml, and 1.0–4.5 mg/dl (160–750
nmol/liter), respectively (9). For 2-wk-old preterm children, the refer-
ence ranges of T4, FT4, and TSH (mean sd) of Williams et al. (10) were
adopted: for GA 23–27 wk, T4 is 4.7  2.6 g/dl (61 nmol/liter), FT4 is
1.4 0.5 ng/dl (18.6 pmol/liter), and TSH is 3.9 2.7 mU/liter; for GA
28–30 wk, T4 is 6.6  2.3 g/dl (85 nmol/liter), FT4 is 1.6  0.4 ng/dl
(21.2 pmol/liter), and TSH is 4.9 11.2 mU/liter; and for GA 31–34 wk,
T4 is 9.1  3.6 g/dl (117 nmol/liter), FT4 is 2.0  0.4 ng/dl (25.2
pmol/liter), and TSH is 3.8  9.3 mU/liter.
Results
Between April 1, 2002, and May 31, 2004, 432,082 children
were born in The Netherlands of whom 430,764 (99.7%)
participated in the neonatal screening program. In total, 772
children (one for every 558 screened children) with an ab-
normal CH screening result were referred, 534 after one heel
puncture, 238 after the second one. In 190 patients (25%)
permanent CH and in 34 (4%) transient CH was diagnosed
(Table 1). Of those children referred because of T4 of3.0 sd
or less (n  474), 72 (15%) had permanent CH, 12 (3%) had
transient CH, and 390 (82%) had no CH (Table 1). All 112
patients with TSH of at least 50 U/ml had CH-T, of whom
the majority (n  110) were diagnosed permanent (Table 2).
Within the permanent CH group, 72 patients (38%) had T4
of3.0 sd or less (Table 1) and 110 (58%) had TSH of at least
50 mU/liter (Table 2); 34 (18%) had TSH less than 20 mU/
liter (Table 2), of whom 15 had CH-C, 13 CH-T, and six CH
not yet specified.
No CH
Of the 548 children classified as no CH, 436 (80%) had GA
more than 36.0wk and BWmore than 2500 g, 49 (9%) hadGA
more than more than 36.0 wk and BW of 2500 g or less, 61
(11%) had GA of 36.0 wk or less and BW more than 2500 g,
and two had GA of 36.0 wk or less and BW of 2500 g or less
(Table 3).
In the group with no CH, 198 children (36%) were already
hospitalized because of severe illness. The primary indica-
tions for hospitalization were asphyxia (n  28), pulmonary
problems (n  61; in 31, extracorporeal membrane oxygen-
ation was necessary), congenital heart defect (n  23), neu-
rological problems (n  5), gastrointestinal problems (n 
11), sepsis (n  12), surgery not otherwise specified (n  6),
dysmorphic features (n  3), or syndromes (n  2). In 47
cases, the indication was not specified. Heel puncture T4,
TSH, and TBG in the group with no CH ranged from 0.8–8.2
g/dl (10–106 nmol/liter), 0.16–18.4 U/ml, and 0.3–3.7
mg/dl (42–613 nmol/liter), respectively; venipuncture FT4
and TSH, measured within 7 d after the heel puncture,
ranged from 0.4–3.0 ng/dl (5.1–38.6 pmol/liter) and 0.16–
18.4 U/ml, respectively.
TBG deficiency was diagnosed in 200 children (36% of
those with no CH), of whom 77 (39%) had total TBG defi-
ciency. Plasma FT4 measured in the first venous blood sam-
ple ranged from 0.5–3.7 ng/dl (6.3–47.8 pmol/liter). Of the
nine children with FT4 less than 0.9 ng/dl (12 pmol/liter),
eight had total TBG deficiency at verification and one had a
very low TBG (0.3mg/dl; 58 nmol/liter) in the heel puncture
(no confirmatory TBGwas available). Of the 12 childrenwith
a plasma FT4 more than 2.3 ng/dl (30 pmol/liter), 11 had
a total TBG deficiency (TBG  0.3 mg/dl).
In seven children, an error was made in the screening
procedure: in two, both 36.0 wk GA or less and 2500 g BW
or less, their GA and BW were not reported correctly on the
filter paper; in two, initial T4 determination, upon which the
child was referred, turned out to be normal after repeated
measurement on the same heel puncture sample (executed
because of themismatch between the results of heel puncture
and venous blood sampling); in one, a second heel puncture,
with an abnormal result, was performed despite a normal
first result; in two, both with T4 of3.0 sd or less and normal
TSH, the filter paper blood spots arrived at the laboratory
with a delay of more than 2 wk.
In 57 children, the abnormal screening results could be
ascribed to an exchange blood transfusion (n 2), a delay of
more than 2 wk in heel puncture sampling (n  9), low BW
(2500 g) in combination with normal GA (36.0 wk) with-
TABLE 1. Classification of CH according to the (first) heel puncture T4
Heel puncture measurements Interpretation
No. of referrals
T4 (SD) TSH (U/ml) No CH Transient CH Permanent CH
T4  3.0 TSH  50 0 0 53 53
20  TSH  50 1 7 3 11
TSH  20 389 5 16 410
Subtotal 390 12 72 474
3.0  T4  0.8 TSH  50 0 2 57 59
20  TSH  50 0 12 43 55
TSH  20a 158 8 18 184
Subtotal 158 22 118 298
Total (of 430,764 screened neonates) 548 34 190 772
Percentage 71 4 25 100
a In combination with a T4/TBG ratio of 8.5 (see also Fig. 1).
TABLE 2. Classification of CH according to the (first) heel
puncture TSH
Heel puncture TSH
(U/ml)
Classification of CH
n
No CH Transient CH Permanent CH
TSH  50 0 2 110 112
20  TSH  50 1 19 46 66
TSH  20 547 13 34 594
Total 548 34 190 772
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out severe illness (n  16) and low GA (36.0 wk) in com-
bination with normal BW (2500 g) without severe illness
(n  30).
In the remaining 86 children, there was no obvious reason
for the abnormal screening results. Their heel puncture T4
concentration ranged from 4.8–10.3 g/dl (62–133 nmol/
liter) with TSH 2–10 U/ml and TBG 1.8–4.1 mg/dl (305–
678 nmol/liter).
Transient CH
In 34 patients, the abnormal CH screening result led to the
diagnosis of transient CH.
Twenty-four were diagnosed with transient CH-T. Their
heel puncture T4 varied from 0.8–13.1 g/dl (10–169 nmol/
liter) and TSHvaried from 18–67U/ml.Nine patientswere
born 36.0 wk GA or earlier, of whom six had BW of 2500 g
or less. Six patients had been exposed to excessive amounts
of iodine during cesarean section (n  1), neonatal surgery
(n  4), and treatment with amiodarone because of cardiac
arrhythmia (n 1); two patients were born to a mother with
autoimmune thyroid disease.
Tenwere diagnosedwith transient CH-C. Their heel punc-
ture T4 varied from 2.7–9.0 g/dl (35–120 nmol/liter), TSH
2–12 U/ml, and TBG 1.7–4.0 mg/dl (288–657 nmol/liter).
All mothers appeared to have Graves’ disease; six were di-
agnosed before pregnancy but inadequately treated through-
out pregnancy; in four, Graves’ disease remained unrecog-
nized until their child was diagnosed with CH-C.
Permanent CH
In 190 patients, the abnormalCH screening result led to the
diagnosis of permanent CH; 16 patients were born 36.0 wk
GA or earlier, of whom 11 had BW of 2500 g or less; 11 had
BW of 2500 g or less and GA more than 36.0 wk.
In this group, 151 patients (79%) had CH-T, 15 patients (8%)
had CH-T21, and 15 patients (8%) had CH-C. In the CH-T
group, 78 (52%) had thyroid dysgenesis and 21 (14%) had thy-
roid dyshormonogenesis, and in 52 (34%), the diagnosis is not
yet further specified (Table 4). In the CH-C group, one patient
had septo-optic dysplasia and one had trisomy 13.
In nine of the 190 patients (5%), insufficient data were avail-
able to classify the origin of the CH as thyroidal or central: one
patient had a congenital nephrotic syndrome (in fact a type of
CHcaused by the loss of thyroid hormone in the urine) and one
had Xp22 deletion with partial trisomy 19p.
CH with normal CH screening result (Table 5)
Three patients (nos. 1 and 2 with permanent CH-T and no.
3 with transient CH-C) had already started T4 supplemen-
tation before the heel puncture was performed. Ten patients
had false-negative screening results.
In one patient with permanent CH-T (no. 4), hypothyroid-
ism was too mild for detection by screening. The coexistence
of Johansson-Blizzard syndrome led to the diagnosis of CH.
The other patient with permanent CH-T (no. 5) was sup-
ported by a heart-lung machine at the time of heel puncture
sampling because of a congenital heart defect. Routine thy-
roid function determination after weaning led to the diag-
nosis of CH.
Of the six patients with permanent CH-C, two were di-
agnosed in the first year after birth because of failure to thrive
(nos. 6 and 7); three, of whom two were born at 36.0 wk GA
or earlier with a BW of 2500 g or less, were diagnosed with
CH-C because of the coexistence of Cornelia de Lange syn-
TABLE 3. Most likely explanation for the abnormal screening results of the 548 referred neonates of 430,764 screened neonates
diagnosed as no CH
Explanation for abnormal
screening result
GA and BW
Total
(n)GA  36.0 wk,
BW  2500 g
GA  36.0 wk,
BW  2500 g
GA  36.0 wk,
BW  2500 g
Severe illness 144 27 27 198
TBG deficiency 191 6 3 200
Error in screening procedure 5 0 0 7c
Exchange blood transfusiona 1 0 1 2
Delayed samplingb 9 0 0 9
Prematurity or dysmaturity 0 16 30 46
No obvious explanation 86 0 0 86
Total, n (%) 436 (80) 49 (9) 61 (11) 548c (100)
a Compared with neonatal blood, adult donor used during exchange blood transfusion contains a lower T4 concentration.
b Heel puncture wasmore than 2 wk delayed. Because, after an initial peak shortly after birth, plasma FT4 concentration gradually decreases
(14), this was considered the reason for the abnormal CH screening result.
c Two children were born 36.0 wk GA or earlier and with 2500 g or less BW, but their GA and BW were not reported correctly on the filter
paper.
TABLE 4. Etiology of permanent CH
Etiology n
CH-T due to thyroid dysgenesis 78 (78, 0)
CH-T due to thyroid dyshormonogenesis 23 (21, 2)
CH-T not yet specified 54 (52, 2)
CH-T21 15 (15, 0)
CH-C 21 (15, 6)a
CH not yet specified 9 (9, 0)
Total 200 (190, 10)a
For each etiology, the number of patients is presented. The num-
bers in parentheses represent the number of patients diagnosed by
screening (first number) and thenumber of patientswith anormalCH
screening result (second number, further specified in Table 5). Thy-
roid dysgenesis means agenesis or hypoplastic or dystopic rudiment.
CH-T not yet specified means that imaging studies were not conclu-
sive about the etiology; CH not yet specified means CH had not yet
been classified as CH-T or CH-C.
a Children with transient CH-C due to maternal Graves’ disease
are not included (see Table 5).
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drome (no. 8), microgenitalism (no. 9), or Prader-Willi syn-
drome (no. 10); one (no. 11)was diagnosed after the diagnosis
CH-C in his twin brother was made (with an abnormal CH
screening result).
In two patients with transient CH-C (nos. 12 and 13) born
to mothers with inadequately treated Graves’ disease,
screening results were not judged abnormal because of the
restricted referral criteria in children with GA of 36.0 wk or
less and BW of 2500 g or less.
Discussion
In 224 (29%) of the 772 children born betweenApril 1, 2002,
and May 31, 2004, and referred because of abnormal screen-
ing results, the diagnosis CH, either permanent or transient,
could be confirmed. Another 13 CH patients, born in the
same period, were not detected by screening. Of them, three
children started with T4 supplementation before heel punc-
ture was performed, and 10 had false-negative screening
results. Sensitivity and specificity of the Dutch screening
approach were 95.8 and 99.9%, respectively.
Among the 430,764 screened children, the incidence of CH
was 1:1,800, of whom 85% had permanent CH (incidence
1:2,200). The incidences of permanent CH-T (1:2,500) and
permanent CH-C (1:21,000) in the present 2002–2004 cohort
are quite similar to those calculated for the cohort of 346,335
children screened in 1981–1982 (1:2,900 and 1:22,000, respec-
tively) (11). These incidence figures belong to the highest
worldwide. Because there is no reason to assume that the
Dutch population has a higher risk of developing CH com-
pared with other well-developed, iodine-repleted countries,
the high number of patients found ismost probably the result
of an efficient screening method detecting CH of variable
etiology, includingmild cases. The incidence of transient CH
is 5- to 6-fold reduced from 1:2,200 in 1981–1982 (11) to
1:12,000 at present. This substantial reduction is probably
because of the reduced perinatal use of iodine-containing
disinfectants and possibly because of reduced use of iodine-
containing x-ray contrast agents.
We classified children with CH-C resulting from inade-
quately treated maternal Graves’ disease as having transient
CH-C because it has been reported that pituitary function
recovers after some time (12, 13). From our present data, an
incidence of 1:33,000 for transient CH-C related to maternal
Graves’ disease could be calculated (n  13), which is sub-
stantially higher than in 1981–1982, when only one of 346,335
screened children had been diagnosed with this type of CH
(11). We have to be aware that even in the present cohort
some cases might have escaped diagnosis. In four mother-
child pairs, the abnormal neonatal screening result was the
first clue to both the infant’s thyrotropic dysfunction and the
mother’s thyroid disease. Therefore, whenever CH-C is sus-
pected, we recommend screening the mother for thyroid
disease in addition to screening of the child for additional
pituitary hormone deficiencies (5).
In two previous publications, it was concluded that the
Dutch T4-TSH-TBG screening approach provided an excel-
lent strategy to detect CH of thyroidal as well as central
origin (4, 6). In the present cohort, early detectionwould have
failed in 47 CH patients, including 15 patients with perma-
nent CH-C, if an elevated TSH concentration had been used
TABLE 5. Reason that CH screening was not abnormal and clue to the diagnosis of CH in the patients with normal CH screening result
ID Type ofCH
Reason that CH screening result
was not abnormal
Clue to the diagnosis
of CH
Heel puncture result
T4
g/dl (nmol/liter)	
T4
(SD)
TSH
(U/ml)
T4/TBG
ratio
1 CH-T Diagnosis and start of T4
supplementation before
screening
Sib with CH-T 15.8 (203) 0.2
2 CH-T Diagnosis and start of T4
supplementation before
screening
Sib with CH-T 8.2 (105) 1.4 24
3 CH-Ca Diagnosis and start of T4
supplementation before
screening
Maternal Graves’ disease 15.3 (197) 1.0
4 CH-T Too mild for detection Sib with CH-T and Johansson-
Blizzard syndrome
9.9 (128) 0.6
5 CH-T Support by heart-lung machine Routine thyroid function deter-
mination
3.1 (40) 2.6 5 12.4
6 CH-C Too mild for detection Failure to thrive 9.6 (123) 1.1 3
7 CH-Cb Too mild for detection Failure to thrive 6.4 (82) 2.0 7 8.3
5.0 (64) 2.4 8 9.2
8 CH-C GA  36 wk and BW  2500 g Cornelia de Lange syndrome 9.6 (123) 0.7
9 CH-C GA  36 wk and BW  2500 g Microgenitalism 4.3 (55) 2.7 3 9.0
10 CH-C Too mild for detection Prader-Willi syndrome 10.9 (140) 0.7
11 CH-C Too mild for detection Twin brother diagnosed with
CH-C
9.6 (124) 1.2 5
12 CH-Ca GA  36 wk and BW  2500 g Maternal Graves’ disease 3.7 (47) 3.0 3 5.7
13 CH-Ca GA  36 wk and BW  2500 g Maternal Graves’ disease 1.2 (16) 4.2 3 4.2
In the first three patients, CH screening results were in fact true normal because T4 supplementation had already started before screening.
Their FT4 concentrations before treatment were 1.1, 0.7, and 0.7 ng/dl and their TSH concentrations were 19.8, 295, and 3.8 mU/liter,
respectively. In the other 10 patients, the CH screening result was really false negative. ID, Numbers that refer to those mentioned in the text.
a Refers to transient CH; all other cases are permanent.
b In this patient, the top numbers refer to the first heel puncture, and the bottom numbers to the second heel puncture.
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as the only referral criterion. Especially in permanent CH-C,
early detection is of vital importance because of the possible
coexistence of other pituitary hormone deficiencies forwhich
adequate and timely supplementation will reduce morbidity
and prevent mortality.
The relatively high number of referred children in whom
the diagnosis of hypothyroidism could not be confirmed at
the time of referral is considered a drawback of the T4-TSH-
TBG approach. In over one third of these false-positive cases,
partial or total TBG deficiency was diagnosed. We chose a
cutoff of 1.8 mg/dl (300 nmol/liter) for the diagnosis of
partial TBG deficiency, even though this is higher than the
lower limit of the reference range as reported in the literature
of 1.3 mg/dl (14) and 1.0 mg/dl (9) in children aged 2–6 wk.
However, because of the high-affinity binding between T4
and TBG, we hold the relatively low TBG responsible for the
lowheel puncture T4 in these children. Determination of TSH
and TBG in all children with T4 of 3.0 sd or less before the
indication for referral was made could have prevented re-
ferral of all 77 cases with total TBG deficiency. However, this
would have caused impermissible delay in referral of those
children with severe CH.
In general, TBG deficiency is considered a harmless con-
dition, not influencing thyroid function. Nevertheless, in
childrenwith total TBGdeficiency,we often encountered FT4
concentrations below as well as above the reference range,
dependent on the FT4 assay used. Indeed, methodological
limitations might make FT4 assays unreliable in case of total
absence of TBG (15, 16). Therefore, the diagnosis of TBG
deficiency should be based on determination of plasma TBG
rather than FT4.
The other major subgroup of referred children in whom
none of the classical types of CH could be diagnosed (about
one fourth of all referrals) consisted of severely ill neonates
hospitalized on an intensive care unit at the time of heel
puncture sampling. Most likely, their severe illness was re-
sponsible for the decreased heel puncture T4, whereas med-
ication or the use of iodine might have transiently disturbed
their thyroid hormone state (17, 18). The decreased heel
puncture T4 in these severely ill children somewhat resem-
bles that of children born prematurely (19). Because early
postnatal T4 levels are strongly related toGAandBW (20, 21),
Dutch children born 36.0 wk or earlier and at 2500 g or less
BW are referred only if screening TSH is elevated. Using this
TSH-only referral criterion also for severely sick children
born at term would have prevented the majority of referrals
in this group. This evokes some important considerations.
First, these patients can only be considered as truly false
positives when the altered thyroid hormone state does not
carry a risk of (preventable) brain damage. Although it is still
a matter of debate whether adult patients with so-called
nonthyroidal illness benefit from T4 supplementation (22,
23), it is as yet unknownwhether neonateswith severe illness
might benefit especially from T4 supplementation in terms of
reduction of long-term morbidity and preservation of brain
development. Furthermore, like in preterm born children,
such adapted referral criteria will hamper the (timely) diag-
nosis of CH-C.
Indeed, during the study period, we encountered four
preterm children with proven CH-C not detected by screen-
ing because of the TSH-only approach for this group. On the
other hand, also in four term children with CH-C, heel punc-
ture T4 concentrations did not indicate referral. The coexist-
ence of a syndrome, microgenitalism, failure to thrive, ma-
ternal Graves’ disease, or a family member with CH-C led to
the diagnosis of CH-C.
The relatively short observational period is considered a
limitation in the detection of false negatives. In the forth-
coming years, more false-negative cases might be identified.
The measurement of T4, TSH, and TBG in all heel puncture
samples will provide the highest chance of detecting patients
with various types of CH (including central CH) as well as
cases with mild CH (including those with normal T4 con-
centrations but elevated TSH). However, this will be a very
costly approach and presumably hardly any extra patient
will be discovered with a preventable risk of brain damage.
Furthermore, with such an approach, patients with mild
CH-C may still escape detection, whereas also some patients
with delayed TSH elevation still escape early detection (as
was presumably the case in patient no. 5 in Table 5).
The present study showed that in 15 patients with trisomy
21, CH was detected by screening, i.e. about 3% of the pa-
tients with trisomy 21 born in the study period. This is quite
similar to the 3.5% reported by van Trotsenburg et al. (24) in
a cohort of Dutch patientswith trisomy 21 born in 1996–1997.
Recently, it has been shown that as a group, these patients
have a persistent mild type of CH, presumably of thyroidal
origin (CH-T21) and that T4 supplementation started early
subtly improves early motor development and growth (8,
25). This indicates that also in patients with mild CH not
related to trisomy 21, it should be established whether T4
supplementation is beneficial for brain development.
In summary, the T4-TSH-TBG screeningmethod as used in
The Netherlands has the potential to detect CH of thyroidal
as well as of central origin, either permanent or transient,
severe or mild. The Dutch incidence figures belong to the
highest worldwide, both for CH-T and CH-C. Among the
referred children in whom the diagnosis of CH could not be
confirmed, TBG deficiency and severe illness could be held
responsible for the great majority of low heel puncture T4
concentrations.
An important pitfall of any screening method is the oc-
currence of false-negative results. For the Dutch CH screen-
ing in particular, this pitfall concerns childrenwith verymild
types of CH having T4 concentrations within the normal
range and prematurely born babies with CH-C.
Neonatal screening has proven its benefits in terms of
improving development in patients with the classical types
of (severe) CH. Future studies should focus on severely ill
neonates and the very mild cases of CH-T and CH-C to
investigate whether these patients might also benefit from
(temporary) T4 supplementation in terms of reduction of
morbidity or improvement of developmental outcome.
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